Portal de Periódicos da CAPES

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

2022; Elsevier BV; Volume: 23; Issue: 10 Linguagem: Inglês

10.1016/s1470-2045(22)00517-4

1474-5488

Alison Tree, Peter Ostler, H. van der Voet, William Chu, Andrew Loblaw, Daniel Ford, Shaun Tolan, Suneil Jain, Alexander S. Martin, John Staffurth, John Armstrong, Philip Camilleri, Kiran Kancherla, J. Frew, Anthony T.�C. Chan, Ian S. Dayes, A. Duffton, Douglas Brand, Daniel Henderson, Kirsty Morrison, Stephanie Brown, Julia Pugh, Stephanie Burnett, Muneeb Mahmud, Victoria Hinder, Olivia Naismith, Emma Hall, Nicholas van As, Éric Lartigau, Suzanne E. Patton, Alan Thompson, Mathias Winkler, Paula Wells, Timothy Lymberiou, Deanna Saunders, Maria Vilarino-Varela, Peter Vavassis, Theodoros Tsakiridis, R Carlson, George Rodrigues, Jean-François Tanguay, Shahid Iqbal, Mathias Winkler, Scott C. Morgan, Alina Mihai, A Li, Omar Din, M. Panadés, Ros Wade, Y. Rimmer, M. Panadés, Nikhil Babu Oommen,

Advanced Radiotherapy Techniques

Localised prostate cancer is commonly treated with external beam radiotherapy and moderate hypofractionation is non-inferior to longer schedules. Stereotactic body radiotherapy (SBRT) allows shorter treatment courses without impacting acute toxicity. We report 2-year toxicity findings from PACE-B, a randomised trial of conventionally fractionated or moderately hypofractionated radiotherapy versus SBRT.